ABBV vs TSLA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Tesla, Inc. · Consumer Cyclical
$343.23
-5.3% upside to fair value
Low Conviction
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
TSLA |
| Current Price |
$208.05 |
$343.23 |
| Fair Value Estimate |
$217.50 |
$325.00 |
| Upside to Fair Value |
+4.5%
|
-5.3%
|
| Market Cap |
$367.9B |
$1,287.9B |
| Forward P/E |
14.9x
|
205.5x
|
| EV / EBITDA |
16.7x
|
108.8x
|
| Price / Sales |
6.1x
|
13.6x
|
| Price / FCF |
20.9x
|
207.1x
|
| Revenue Growth YoY |
+8.6%
|
-2.9%
|
| Gross Margin |
83.7%
|
18.0%
|
| Operating Margin |
34.7%
|
4.6%
|
| Return on Equity |
-129.24%
|
4.8%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
0.48%
|
| Analyst Consensus |
Buy
|
—
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Tesla remains the most polarizing stock in markets. The core auto business is deteriorating: FY2025 revenue fell 2.9% to $94.8B, net income dropped 46.8% to $3.8B, and Q4 deliveries declined 15.6% YoY to 418K units. Yet the stock trades at 13.6x TTM P/S (near 5yr highs) on the optionality of Cybercab robotaxis launching April 2026, FSD reaching unsupervised status in Austin, and Optimus humanoid …
Accumulation Zones
| Metric |
ABBV |
TSLA |
| Zone Low |
$163.13 |
$244.00 |
| Zone High |
$184.88 |
$276.00 |
| In Buy Zone? |
No
|
No
|